{"transactions":[{"id":4621576,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":37240,"kind":"person","name":"Heffernan Michael Thomas","position":1,"cik":"0001448914","reported_name":"Heffernan Michael Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-09-17T20:55:22.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":21052,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These options were granted on December 20, 2017. The 21,052 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These options, which were awarded on December 20, 2017, would otherwise expire and become forfeitable on December 19, 2027."}],"balance_after":0,"derivative":{"exercise_price":3.33,"underlying":"Common Stock","underlying_shares":21052},"source":{"system":"sec-edgar","filing":"0001193125-26-394456","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526394456/ownership.xml","form_type":"4"}},{"id":4621575,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":37240,"kind":"person","name":"Heffernan Michael Thomas","position":1,"cik":"0001448914","reported_name":"Heffernan Michael Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-09-17T20:55:22.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":false,"shares":18421,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options were granted on February 28, 2017. The 18,421 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These options, which were awarded on February 28, 2017, would otherwise expire and become forfeitable on February 27, 2027."}],"balance_after":0,"derivative":{"exercise_price":3.04,"underlying":"Common Stock","underlying_shares":18421},"source":{"system":"sec-edgar","filing":"0001193125-26-394456","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526394456/ownership.xml","form_type":"4"}},{"id":4621574,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":37240,"kind":"person","name":"Heffernan Michael Thomas","position":1,"cik":"0001448914","reported_name":"Heffernan Michael Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T20:55:22.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":100,"price":15.88,"value":1588.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026."}],"balance_after":6351,"source":{"system":"sec-edgar","filing":"0001193125-26-394456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526394456/ownership.xml","form_type":"4"}},{"id":4621573,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":37240,"kind":"person","name":"Heffernan Michael Thomas","position":1,"cik":"0001448914","reported_name":"Heffernan Michael Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T20:55:22.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":20952,"price":15.09,"value":316165.68,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026."}],"balance_after":6451,"source":{"system":"sec-edgar","filing":"0001193125-26-394456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526394456/ownership.xml","form_type":"4"}},{"id":4621572,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":37240,"kind":"person","name":"Heffernan Michael Thomas","position":1,"cik":"0001448914","reported_name":"Heffernan Michael Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T20:55:22.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":21052,"price":3.33,"value":70103.16,"ownership":{"direct":true},"balance_after":27403,"source":{"system":"sec-edgar","filing":"0001193125-26-394456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526394456/ownership.xml","form_type":"4"}},{"id":4621571,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":37240,"kind":"person","name":"Heffernan Michael Thomas","position":1,"cik":"0001448914","reported_name":"Heffernan Michael Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T20:55:22.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":100,"price":15.88,"value":1588.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026."}],"balance_after":6351,"source":{"system":"sec-edgar","filing":"0001193125-26-394456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526394456/ownership.xml","form_type":"4"}},{"id":4621570,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":37240,"kind":"person","name":"Heffernan Michael Thomas","position":1,"cik":"0001448914","reported_name":"Heffernan Michael Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T20:55:22.000Z","date":"2026-09-15","kind":"sale","planned":true,"acquired":false,"shares":18321,"price":15.09,"value":276463.89,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026."}],"balance_after":6451,"source":{"system":"sec-edgar","filing":"0001193125-26-394456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526394456/ownership.xml","form_type":"4"}},{"id":4621569,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":37240,"kind":"person","name":"Heffernan Michael Thomas","position":1,"cik":"0001448914","reported_name":"Heffernan Michael Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-17T20:55:22.000Z","date":"2026-09-15","kind":"exercise","planned":true,"acquired":true,"shares":18421,"price":3.04,"value":55999.84,"ownership":{"direct":true},"balance_after":24772,"source":{"system":"sec-edgar","filing":"0001193125-26-394456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526394456/ownership.xml","form_type":"4"}},{"id":749348,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2026-06-04T20:28:16.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":35000,"derivative":{"exercise_price":13.45,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-257488","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000119312526257488/ownership.xml","form_type":"4"}},{"id":749351,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41270,"kind":"person","name":"Colangelo Dominick","position":1,"cik":"0001313403","reported_name":"Colangelo Dominick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2026-06-04T20:05:08.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":35000,"derivative":{"exercise_price":13.45,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-257370","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1313403/000119312526257370/ownership.xml","form_type":"4"}},{"id":749302,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2026-06-04T20:05:05.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":35000,"derivative":{"exercise_price":13.45,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-257373","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000119312526257373/ownership.xml","form_type":"4"}},{"id":749388,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2026-06-04T20:05:04.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":35000,"derivative":{"exercise_price":13.45,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-257371","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000119312526257371/ownership.xml","form_type":"4"}},{"id":749483,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":37240,"kind":"person","name":"Heffernan Michael Thomas","position":1,"cik":"0001448914","reported_name":"Heffernan Michael Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2026-06-04T20:05:03.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":35000,"derivative":{"exercise_price":13.45,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-257366","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448914/000119312526257366/ownership.xml","form_type":"4"}},{"id":890412,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-20T21:16:12.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":675000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 19, 2026. The 675,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer."}],"balance_after":675000,"derivative":{"exercise_price":10.56,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":675000},"source":{"system":"sec-edgar","filing":"0001193125-26-061391","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000119312526061391/ownership.xml","form_type":"4"}},{"id":890256,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-20T21:15:50.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 19, 2026. The 160,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer."}],"balance_after":160000,"derivative":{"exercise_price":10.56,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001193125-26-061385","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526061385/ownership.xml","form_type":"4"}},{"id":890509,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65406,"kind":"person","name":"Cassella James V","position":1,"cik":"0001353528","reported_name":"Cassella James V","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-20T16:17:06.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":215000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 19, 2026. The 215,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer."}],"balance_after":215000,"derivative":{"exercise_price":10.56,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":215000},"source":{"system":"sec-edgar","filing":"0001193125-26-061399","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353528/000119312526061399/ownership.xml","form_type":"4"}},{"id":890592,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-20T16:16:45.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 19, 2026. The 35,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer."}],"balance_after":35000,"derivative":{"exercise_price":10.56,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-061396","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000119312526061396/ownership.xml","form_type":"4"}},{"id":890429,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-20T16:16:27.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 19, 2026. The 85,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer."}],"balance_after":85000,"derivative":{"exercise_price":10.56,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001193125-26-061394","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000119312526061394/ownership.xml","form_type":"4"}},{"id":904879,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"3.5-Year Common Stock Warrant","published_at":"2026-02-13T21:30:23.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":false,"shares":1851852,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":1.37,"exercise_date":"2021-10-18","expiration_date":"2025-04-18","underlying":"Common Stock","underlying_shares":1851852},"source":{"system":"sec-edgar","filing":"0001193125-26-051548","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526051548/ownership.xml","form_type":"5"}},{"id":904878,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":23294,"kind":"person","name":"SANDELL SCOTT D","position":1,"cik":"0001237289","reported_name":"SANDELL SCOTT D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T21:30:23.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":true,"shares":1851852,"price":1.37,"value":2537037.24,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":12273280,"source":{"system":"sec-edgar","filing":"0001193125-26-051548","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237289/000119312526051548/ownership.xml","form_type":"5"}},{"id":904744,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"3.5-Year Common Stock Warrant","published_at":"2026-02-13T21:30:23.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":false,"shares":1851852,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":1.37,"exercise_date":"2021-10-18","expiration_date":"2025-04-18","underlying":"Common Stock","underlying_shares":1851852},"source":{"system":"sec-edgar","filing":"0001193125-26-051530","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526051530/ownership.xml","form_type":"5"}},{"id":904743,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":23293,"kind":"person","name":"Florence Anthony A. Jr.","position":1,"cik":"0001559827","reported_name":"Florence Anthony A. Jr.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T21:30:23.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":true,"shares":1851852,"price":1.37,"value":2537037.24,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":12273280,"source":{"system":"sec-edgar","filing":"0001193125-26-051530","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1559827/000119312526051530/ownership.xml","form_type":"5"}},{"id":904728,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"3.5-Year Common Stock Warrant","published_at":"2026-02-13T21:30:19.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":false,"shares":1851852,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":1.37,"exercise_date":"2021-10-18","expiration_date":"2025-04-18","underlying":"Common Stock","underlying_shares":1851852},"source":{"system":"sec-edgar","filing":"0001193125-26-051545","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526051545/ownership.xml","form_type":"5"}},{"id":904727,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T21:30:19.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":true,"shares":1851852,"price":1.37,"value":2537037.24,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":12273280,"source":{"system":"sec-edgar","filing":"0001193125-26-051545","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526051545/ownership.xml","form_type":"5"}},{"id":904726,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"3.5-Year Common Stock Warrant","published_at":"2026-02-13T21:30:16.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":false,"shares":1851852,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":1.37,"exercise_date":"2021-10-18","expiration_date":"2025-04-18","underlying":"Common Stock","underlying_shares":1851852},"source":{"system":"sec-edgar","filing":"0001193125-26-051525","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526051525/ownership.xml","form_type":"5"}},{"id":904725,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":23295,"kind":"person","name":"Makhzoumi Mohamad","position":1,"cik":"0001630226","reported_name":"Makhzoumi Mohamad","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T21:30:16.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":true,"shares":1851852,"price":1.37,"value":2537037.24,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":12273280,"source":{"system":"sec-edgar","filing":"0001193125-26-051525","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526051525/ownership.xml","form_type":"5"}},{"id":904724,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"3.5-Year Common Stock Warrant","published_at":"2026-02-13T21:30:04.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":false,"shares":1851852,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":1.37,"exercise_date":"2021-10-18","expiration_date":"2025-04-18","underlying":"Common Stock","underlying_shares":1851852},"source":{"system":"sec-edgar","filing":"0001193125-26-051517","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526051517/ownership.xml","form_type":"5"}},{"id":904723,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":38171,"kind":"person","name":"Chang Carmen","position":1,"cik":"0001746342","reported_name":"Chang Carmen","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T21:30:04.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":true,"shares":1851852,"price":1.37,"value":2537037.24,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":12273280,"source":{"system":"sec-edgar","filing":"0001193125-26-051517","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526051517/ownership.xml","form_type":"5"}},{"id":904863,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"3.5-Year Common Stock Warrant","published_at":"2026-02-13T16:30:18.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":false,"shares":1851852,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":1.37,"exercise_date":"2021-10-18","expiration_date":"2025-04-18","underlying":"Common Stock","underlying_shares":1851852},"source":{"system":"sec-edgar","filing":"0001193125-26-051528","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000119312526051528/ownership.xml","form_type":"5"}},{"id":904862,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":61210,"kind":"person","name":"BASKETT FOREST","position":1,"cik":"0001277631","reported_name":"BASKETT FOREST","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T16:30:18.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":true,"shares":1851852,"price":1.37,"value":2537037.24,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":12273280,"source":{"system":"sec-edgar","filing":"0001193125-26-051528","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1277631/000119312526051528/ownership.xml","form_type":"5"}},{"id":904746,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"3.5-Year Common Stock Warrant","published_at":"2026-02-13T16:30:11.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":false,"shares":1851852,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":1.37,"exercise_date":"2021-10-18","expiration_date":"2025-04-18","underlying":"Common Stock","underlying_shares":1851852},"source":{"system":"sec-edgar","filing":"0001193125-26-051520","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526051520/ownership.xml","form_type":"5"}},{"id":904745,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":61190,"kind":"person","name":"Walker Paul Edward","position":1,"cik":"0001553150","reported_name":"Walker Paul Edward","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T16:30:11.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":true,"shares":1851852,"price":1.37,"value":2537037.24,"ownership":{"direct":false,"nature":"See Note 1"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 16 securities in which the Reporting Person has no pecuniary interest."}],"balance_after":12273280,"source":{"system":"sec-edgar","filing":"0001193125-26-051520","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553150/000119312526051520/ownership.xml","form_type":"5"}},{"id":905256,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":66498,"kind":"organization","name":"New Enterprise Associates 16, L.P.","position":1,"cik":"0001694560","reported_name":"New Enterprise Associates 16, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":66499,"kind":"organization","name":"NEA Partners 16, L.P.","position":2,"cik":"0001712881","reported_name":"NEA Partners 16, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":66500,"kind":"organization","name":"NEA 16 GP, LLC","position":3,"cik":"0001712882","reported_name":"NEA 16 GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"3.5-Year Common Stock Warrant","published_at":"2026-02-13T16:30:09.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":false,"shares":1851852,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by NEA 16, and indirectly held by NEA Partners 16, L.P. (\"NEA Partners\"), the sole general partner of NEA 16, NEA 16 GP, LLC (\"NEA 16 GP\"), the sole general partner of NEA Partners 16, and the individual managers of NEA 16 GP (NEA Partners 16, NEA 16 GP and the individual managers of NEA 16 GP (collectively, the \"Managers\"), together, the \"Indirect Reporting Persons\"). The Managers of NEA 16 GP are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad Makhzoumi, Scott D. Sandell and Paul Walker. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Indirect Reporting Persons have no pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":1.37,"exercise_date":"2021-10-18","expiration_date":"2025-04-18","underlying":"Common Stock","underlying_shares":1851852},"source":{"system":"sec-edgar","filing":"0001193125-26-051537","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1712881/000119312526051537/ownership.xml","form_type":"5"}},{"id":905255,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":66498,"kind":"organization","name":"New Enterprise Associates 16, L.P.","position":1,"cik":"0001694560","reported_name":"New Enterprise Associates 16, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":66499,"kind":"organization","name":"NEA Partners 16, L.P.","position":2,"cik":"0001712881","reported_name":"NEA Partners 16, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":66500,"kind":"organization","name":"NEA 16 GP, LLC","position":3,"cik":"0001712882","reported_name":"NEA 16 GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-13T16:30:09.000Z","date":"2025-04-17","kind":"other","planned":false,"acquired":true,"shares":1851852,"price":1.37,"value":2537037.24,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities are directly held by NEA 16, and indirectly held by NEA Partners 16, L.P. (\"NEA Partners\"), the sole general partner of NEA 16, NEA 16 GP, LLC (\"NEA 16 GP\"), the sole general partner of NEA Partners 16, and the individual managers of NEA 16 GP (NEA Partners 16, NEA 16 GP and the individual managers of NEA 16 GP (collectively, the \"Managers\"), together, the \"Indirect Reporting Persons\"). The Managers of NEA 16 GP are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad Makhzoumi, Scott D. Sandell and Paul Walker. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Indirect Reporting Persons have no pecuniary interest."}],"balance_after":12273280,"source":{"system":"sec-edgar","filing":"0001193125-26-051537","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1712881/000119312526051537/ownership.xml","form_type":"5"}},{"id":940865,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":34527,"kind":"person","name":"HASTINGS DAVID C","position":1,"cik":"0001237401","reported_name":"HASTINGS DAVID C","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-12T21:05:09.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":375000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 8, 2026. The 375,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on January 8, 2027 and as to the remaining 75% of the shares in equal monthly installments thereafter through January 8, 2030."}],"balance_after":375000,"derivative":{"exercise_price":11.21,"expiration_date":"2036-01-07","underlying":"Common Stock","underlying_shares":375000},"source":{"system":"sec-edgar","filing":"0001193125-26-010361","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1237401/000119312526010361/ownership.xml","form_type":"4"}},{"id":981437,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-03T16:16:39.000Z","date":"2025-12-02","kind":"exercise","planned":false,"acquired":false,"shares":4225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on February 11, 2022. The 35,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":15775,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":4225},"source":{"system":"sec-edgar","filing":"0001193125-25-306729","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000119312525306729/ownership.xml","form_type":"4"}},{"id":981436,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-03T16:16:39.000Z","date":"2025-12-02","kind":"exercise","planned":false,"acquired":true,"shares":4225,"price":0.511,"value":2158.975,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 6,870 shares purchased through the Issuer's employee stock purchase plan."}],"balance_after":26095,"source":{"system":"sec-edgar","filing":"0001193125-25-306729","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000119312525306729/ownership.xml","form_type":"4"}},{"id":1111212,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":24544,"kind":"person","name":"Mathers Edward T","position":1,"cik":"0001328625","reported_name":"Mathers Edward T","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2025-06-13T20:09:28.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2025. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":45000,"derivative":{"exercise_price":6.25,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000950170-25-086165","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1328625/000095017025086165/ownership.xml","form_type":"4"}},{"id":1111238,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41270,"kind":"person","name":"Colangelo Dominick","position":1,"cik":"0001313403","reported_name":"Colangelo Dominick","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2025-06-13T20:00:23.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2025. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":45000,"derivative":{"exercise_price":6.25,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000950170-25-086112","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1313403/000095017025086112/ownership.xml","form_type":"4"}},{"id":1111488,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":37240,"kind":"person","name":"Heffernan Michael Thomas","position":1,"cik":"0001448914","reported_name":"Heffernan Michael Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2025-06-13T20:00:22.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2025. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":45000,"derivative":{"exercise_price":6.25,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000950170-25-086111","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448914/000095017025086111/ownership.xml","form_type":"4"}},{"id":1111293,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":41284,"kind":"person","name":"VANLENT ANNE","position":1,"cik":"0001229243","reported_name":"VANLENT ANNE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2025-06-13T20:00:19.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2025. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":45000,"derivative":{"exercise_price":6.25,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000950170-25-086110","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229243/000095017025086110/ownership.xml","form_type":"4"}},{"id":1111170,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Nonstatutory Stock Option (right to buy)","published_at":"2025-06-13T20:00:18.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 11, 2025. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer."}],"balance_after":45000,"derivative":{"exercise_price":6.25,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000950170-25-086109","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000095017025086109/ownership.xml","form_type":"4"}},{"id":1124278,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-06-03T20:00:35.000Z","date":"2025-05-31","kind":"grant","planned":false,"acquired":true,"shares":72000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. On May 31, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the CORAL trial were satisfied, resulting in the vesting of the option as to 72,000 shares of common stock."}],"balance_after":110400,"derivative":{"exercise_price":2.38,"exercise_date":"2025-05-31","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0000950170-25-080886","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025080886/ownership.xml","form_type":"4"}},{"id":1124277,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-06-03T20:00:33.000Z","date":"2025-05-31","kind":"grant","planned":false,"acquired":true,"shares":72000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. On May 31, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the CORAL trial were satisfied, resulting in the vesting of the option as to 72,000 shares of common stock."}],"balance_after":110400,"derivative":{"exercise_price":2.38,"exercise_date":"2025-05-31","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":72000},"source":{"system":"sec-edgar","filing":"0000950170-25-080885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025080885/ownership.xml","form_type":"4"}},{"id":1124544,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-06-03T20:00:29.000Z","date":"2025-05-31","kind":"grant","planned":false,"acquired":true,"shares":102000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 170,000 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 54,400 shares of common stock. On May 31, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the CORAL trial were satisfied, resulting in the vesting of the option as to 102,000 shares of common stock."}],"balance_after":156400,"derivative":{"exercise_price":2.38,"exercise_date":"2025-05-31","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":102000},"source":{"system":"sec-edgar","filing":"0000950170-25-080883","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017025080883/ownership.xml","form_type":"4"}},{"id":1124792,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-06-03T16:00:39.000Z","date":"2025-05-31","kind":"grant","planned":false,"acquired":true,"shares":8550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 14,250 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 4,560 shares of common stock. On May 31, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the CORAL trial were satisfied, resulting in the vesting of the option as to 8,550 shares of common stock."}],"balance_after":13110,"derivative":{"exercise_price":2.38,"exercise_date":"2025-05-31","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":8550},"source":{"system":"sec-edgar","filing":"0000950170-25-080889","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000095017025080889/ownership.xml","form_type":"4"}},{"id":1124543,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-06-03T16:00:37.000Z","date":"2025-05-31","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 100,000 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 32,000 shares of common stock. On May 31, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the CORAL trial were satisfied, resulting in the vesting of the option as to 60,000 shares of common stock."}],"balance_after":92000,"derivative":{"exercise_price":2.38,"exercise_date":"2025-05-31","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-25-080887","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017025080887/ownership.xml","form_type":"4"}},{"id":1190738,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-26T16:30:14.000Z","date":"2025-03-25","kind":"exercise","planned":false,"acquired":false,"shares":2631,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on May 15, 2015. The 2,631 shares of common stock underlying the option vested as to 25% of the shares on May 15, 2016 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through May 15, 2019."}],"balance_after":0,"derivative":{"exercise_price":1.43,"expiration_date":"2025-05-14","underlying":"Common Stock","underlying_shares":2631},"source":{"system":"sec-edgar","filing":"0000950170-25-045295","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017025045295/ownership.xml","form_type":"4"}},{"id":1190737,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-26T16:30:14.000Z","date":"2025-03-25","kind":"sale","planned":false,"acquired":false,"shares":2631,"price":6.6,"value":17364.6,"ownership":{"direct":true},"balance_after":221373,"source":{"system":"sec-edgar","filing":"0000950170-25-045295","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017025045295/ownership.xml","form_type":"4"}},{"id":1190736,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-26T16:30:14.000Z","date":"2025-03-25","kind":"exercise","planned":false,"acquired":true,"shares":2631,"price":1.43,"value":3762.33,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,058 shares purchased through the Issuer's employee stock purchase plan."}],"balance_after":224004,"source":{"system":"sec-edgar","filing":"0000950170-25-045295","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017025045295/ownership.xml","form_type":"4"}},{"id":1192093,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-25T20:30:04.000Z","date":"2025-03-21","kind":"exercise","planned":false,"acquired":false,"shares":5263,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on May 15, 2015. The 5,263 shares of common stock underlying the option vested as to 25% of the shares on May 15, 2016 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through May 15, 2019."}],"balance_after":0,"derivative":{"exercise_price":1.43,"expiration_date":"2025-05-14","underlying":"Common Stock","underlying_shares":5263},"source":{"system":"sec-edgar","filing":"0000950170-25-044436","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017025044436/ownership.xml","form_type":"4"}},{"id":1192092,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-03-25T20:30:04.000Z","date":"2025-03-21","kind":"sale","planned":false,"acquired":false,"shares":5263,"price":6.5789,"value":34624.7507,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.55 to $6.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":213313,"source":{"system":"sec-edgar","filing":"0000950170-25-044436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017025044436/ownership.xml","form_type":"4"}},{"id":1192091,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-03-25T20:30:04.000Z","date":"2025-03-21","kind":"exercise","planned":false,"acquired":true,"shares":5263,"price":1.43,"value":7526.09,"ownership":{"direct":true},"balance_after":218576,"source":{"system":"sec-edgar","filing":"0000950170-25-044436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017025044436/ownership.xml","form_type":"4"}},{"id":1209390,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-03-12T20:00:10.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":54400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 170,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 54,400 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied."}],"balance_after":54400,"derivative":{"exercise_price":2.38,"exercise_date":"2025-03-10","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":54400},"source":{"system":"sec-edgar","filing":"0000950170-25-037886","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017025037886/ownership.xml","form_type":"4"}},{"id":1209180,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-03-12T20:00:09.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":38400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied."}],"balance_after":38400,"derivative":{"exercise_price":2.38,"exercise_date":"2025-03-10","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":38400},"source":{"system":"sec-edgar","filing":"0000950170-25-037884","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037884/ownership.xml","form_type":"4"}},{"id":1209189,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"exercise","planned":true,"acquired":false,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":18750,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209188,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"exercise","planned":true,"acquired":false,"shares":63813,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on September 22, 2020. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on September 22, 2021 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through September 22, 2024."}],"balance_after":11187,"derivative":{"exercise_price":3.91,"expiration_date":"2030-09-22","underlying":"Common Stock","underlying_shares":63813},"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209187,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"exercise","planned":true,"acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 17,500 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis."}],"balance_after":0,"derivative":{"exercise_price":3.21,"expiration_date":"2031-02-16","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209186,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"grant","planned":true,"acquired":true,"shares":38400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied."}],"balance_after":38400,"derivative":{"exercise_price":2.38,"exercise_date":"2025-03-10","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":38400},"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209185,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"sale","planned":true,"acquired":false,"shares":4350,"price":7.1498,"value":31101.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.14 to $7.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":76900,"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209184,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"sale","planned":true,"acquired":false,"shares":76963,"price":6.7276,"value":517776.2788,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.14 to $7.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":81250,"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209183,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"exercise","planned":true,"acquired":true,"shares":31250,"price":0.511,"value":15968.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024."}],"balance_after":158213,"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209182,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"exercise","planned":true,"acquired":true,"shares":63813,"price":3.91,"value":249508.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024."}],"balance_after":126963,"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209181,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-12T20:00:04.000Z","date":"2025-03-10","kind":"exercise","planned":true,"acquired":true,"shares":17500,"price":3.21,"value":56175.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024."}],"balance_after":63150,"source":{"system":"sec-edgar","filing":"0000950170-25-037880","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025037880/ownership.xml","form_type":"4"}},{"id":1209391,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-03-12T16:00:07.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 100,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 32,000 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied."}],"balance_after":32000,"derivative":{"exercise_price":2.38,"exercise_date":"2025-03-10","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0000950170-25-037883","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017025037883/ownership.xml","form_type":"4"}},{"id":1209560,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-03-12T16:00:06.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":4560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 14,250 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 4,560 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied."}],"balance_after":4560,"derivative":{"exercise_price":2.38,"exercise_date":"2025-03-10","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":4560},"source":{"system":"sec-edgar","filing":"0000950170-25-037882","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000095017025037882/ownership.xml","form_type":"4"}},{"id":1255140,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":28988,"kind":"person","name":"Simon Farrell","position":1,"cik":"0001965585","reported_name":"Simon Farrell","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-20T21:00:10.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":225500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 18, 2025. The 225,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029."}],"balance_after":225500,"derivative":{"exercise_price":4.22,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":225500},"source":{"system":"sec-edgar","filing":"0000950170-25-024114","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025024114/ownership.xml","form_type":"4"}},{"id":1255141,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-20T21:00:05.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":225500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 18, 2025. The 225,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029."}],"balance_after":225500,"derivative":{"exercise_price":4.22,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":225500},"source":{"system":"sec-edgar","filing":"0000950170-25-024111","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025024111/ownership.xml","form_type":"4"}},{"id":1255328,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-20T21:00:03.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":811000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 18, 2025. The 811,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029."}],"balance_after":811000,"derivative":{"exercise_price":4.22,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":811000},"source":{"system":"sec-edgar","filing":"0000950170-25-024110","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017025024110/ownership.xml","form_type":"4"}},{"id":1255329,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-20T16:00:14.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":116000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 18, 2025. The 116,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029."}],"balance_after":116000,"derivative":{"exercise_price":4.22,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":116000},"source":{"system":"sec-edgar","filing":"0000950170-25-024117","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017025024117/ownership.xml","form_type":"4"}},{"id":1255484,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65406,"kind":"person","name":"Cassella James V","position":1,"cik":"0001353528","reported_name":"Cassella James V","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-20T16:00:11.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":257500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 18, 2025. The 257,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029."}],"balance_after":257500,"derivative":{"exercise_price":4.22,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":257500},"source":{"system":"sec-edgar","filing":"0000950170-25-024116","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353528/000095017025024116/ownership.xml","form_type":"4"}},{"id":1255647,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-20T16:00:03.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 18, 2025. The 41,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029."}],"balance_after":41000,"derivative":{"exercise_price":4.22,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0000950170-25-024109","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000095017025024109/ownership.xml","form_type":"4"}},{"id":1304914,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-10T21:14:48.000Z","date":"2025-01-08","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":42125,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000950170-25-004164","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025004164/ownership.xml","form_type":"4"}},{"id":1304913,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-10T21:14:48.000Z","date":"2025-01-07","kind":"exercise","planned":false,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":47125,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0000950170-25-004164","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025004164/ownership.xml","form_type":"4"}},{"id":1304912,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-10T21:14:48.000Z","date":"2025-01-08","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":0.511,"value":2555.0,"ownership":{"direct":true},"balance_after":64660,"source":{"system":"sec-edgar","filing":"0000950170-25-004164","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025004164/ownership.xml","form_type":"4"}},{"id":1304911,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":78914,"kind":"person","name":"Delfini Lisa","position":1,"cik":"0001873253","reported_name":"Delfini Lisa","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-01-10T21:14:48.000Z","date":"2025-01-07","kind":"exercise","planned":false,"acquired":true,"shares":1000,"price":0.511,"value":511.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 5,381 shares purchased through the Issuer's employee stock purchase plan."}],"balance_after":59660,"source":{"system":"sec-edgar","filing":"0000950170-25-004164","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025004164/ownership.xml","form_type":"4"}},{"id":1328528,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2024-12-17T16:30:03.000Z","date":"2024-12-13","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on February 11, 2022. The 35,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":20000,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-24-137255","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000095017024137255/ownership.xml","form_type":"4"}},{"id":1328527,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65410,"kind":"person","name":"Galletta Christopher","position":1,"cik":"0001486099","reported_name":"Galletta Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-12-17T16:30:03.000Z","date":"2024-12-13","kind":"exercise","planned":false,"acquired":true,"shares":15000,"price":0.511,"value":7665.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 4,935 shares purchased through the Issuer's employee stock purchase plan."}],"balance_after":19935,"source":{"system":"sec-edgar","filing":"0000950170-24-137255","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1486099/000095017024137255/ownership.xml","form_type":"4"}},{"id":1396654,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65406,"kind":"person","name":"Cassella James V","position":1,"cik":"0001353528","reported_name":"Cassella James V","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-10-01T17:04:21.000Z","date":"2024-09-30","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on September 30, 2024. The 400,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on September 30, 2025 and as to the remaining 75% of the shares in equal monthly installments thereafter, through September 30, 2028."}],"balance_after":400000,"derivative":{"exercise_price":3.34,"expiration_date":"2034-09-29","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0000950170-24-110921","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1353528/000095017024110921/ownership.xml","form_type":"4"}},{"id":1411768,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-09T21:00:57.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":false,"shares":1840,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on November 25, 2014. The 61,180 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018."}],"balance_after":0,"derivative":{"exercise_price":1.43,"expiration_date":"2024-11-24","underlying":"Common Stock","underlying_shares":1840},"source":{"system":"sec-edgar","filing":"0000950170-24-104804","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017024104804/ownership.xml","form_type":"4"}},{"id":1411767,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-09T21:00:57.000Z","date":"2024-09-06","kind":"exercise","planned":false,"acquired":false,"shares":4219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on November 25, 2014. The 61,180 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018."}],"balance_after":1840,"derivative":{"exercise_price":1.43,"expiration_date":"2024-11-24","underlying":"Common Stock","underlying_shares":4219},"source":{"system":"sec-edgar","filing":"0000950170-24-104804","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017024104804/ownership.xml","form_type":"4"}},{"id":1411766,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-09-09T21:00:57.000Z","date":"2024-09-09","kind":"sale","planned":false,"acquired":false,"shares":1840,"price":3.0362,"value":5586.608,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.010 to $3.085 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":213313,"source":{"system":"sec-edgar","filing":"0000950170-24-104804","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017024104804/ownership.xml","form_type":"4"}},{"id":1411765,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-09-09T21:00:57.000Z","date":"2024-09-09","kind":"exercise","planned":false,"acquired":true,"shares":1840,"price":1.43,"value":2631.2,"ownership":{"direct":true},"balance_after":215153,"source":{"system":"sec-edgar","filing":"0000950170-24-104804","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017024104804/ownership.xml","form_type":"4"}},{"id":1411764,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-09-09T21:00:57.000Z","date":"2024-09-06","kind":"sale","planned":false,"acquired":false,"shares":4219,"price":3.0302,"value":12784.4138,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":213313,"source":{"system":"sec-edgar","filing":"0000950170-24-104804","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017024104804/ownership.xml","form_type":"4"}},{"id":1411763,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-09-09T21:00:57.000Z","date":"2024-09-06","kind":"exercise","planned":false,"acquired":true,"shares":4219,"price":1.43,"value":6033.17,"ownership":{"direct":true},"balance_after":217532,"source":{"system":"sec-edgar","filing":"0000950170-24-104804","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017024104804/ownership.xml","form_type":"4"}},{"id":1413671,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-05T20:54:52.000Z","date":"2024-09-05","kind":"exercise","planned":false,"acquired":false,"shares":40277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on November 25, 2014. The 61,180 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018."}],"balance_after":6059,"derivative":{"exercise_price":1.43,"expiration_date":"2024-11-24","underlying":"Common Stock","underlying_shares":40277},"source":{"system":"sec-edgar","filing":"0000950170-24-104061","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017024104061/ownership.xml","form_type":"4"}},{"id":1413670,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-05T20:54:52.000Z","date":"2024-09-04","kind":"exercise","planned":false,"acquired":false,"shares":10981,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on November 25, 2014. The 61,180 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018."}],"balance_after":46336,"derivative":{"exercise_price":1.43,"expiration_date":"2024-11-24","underlying":"Common Stock","underlying_shares":10981},"source":{"system":"sec-edgar","filing":"0000950170-24-104061","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017024104061/ownership.xml","form_type":"4"}},{"id":1413669,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-05T20:54:52.000Z","date":"2024-09-03","kind":"exercise","planned":false,"acquired":false,"shares":3863,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on November 25, 2014. The 61,180 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018."}],"balance_after":57317,"derivative":{"exercise_price":1.43,"expiration_date":"2024-11-24","underlying":"Common Stock","underlying_shares":3863},"source":{"system":"sec-edgar","filing":"0000950170-24-104061","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017024104061/ownership.xml","form_type":"4"}},{"id":1413668,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-09-05T20:54:52.000Z","date":"2024-09-05","kind":"sale","planned":false,"acquired":false,"shares":40277,"price":3.1112,"value":125309.8024,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":213313,"source":{"system":"sec-edgar","filing":"0000950170-24-104061","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017024104061/ownership.xml","form_type":"4"}},{"id":1413667,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-09-05T20:54:52.000Z","date":"2024-09-05","kind":"exercise","planned":false,"acquired":true,"shares":40277,"price":1.43,"value":57596.11,"ownership":{"direct":true},"balance_after":253590,"source":{"system":"sec-edgar","filing":"0000950170-24-104061","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017024104061/ownership.xml","form_type":"4"}},{"id":1413666,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-09-05T20:54:52.000Z","date":"2024-09-04","kind":"sale","planned":false,"acquired":false,"shares":10981,"price":3.0239,"value":33205.4459,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.02 to $3.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":213313,"source":{"system":"sec-edgar","filing":"0000950170-24-104061","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017024104061/ownership.xml","form_type":"4"}},{"id":1413665,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-09-05T20:54:52.000Z","date":"2024-09-04","kind":"exercise","planned":false,"acquired":true,"shares":10981,"price":1.43,"value":15702.83,"ownership":{"direct":true},"balance_after":224294,"source":{"system":"sec-edgar","filing":"0000950170-24-104061","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017024104061/ownership.xml","form_type":"4"}},{"id":1413664,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-09-05T20:54:52.000Z","date":"2024-09-03","kind":"sale","planned":false,"acquired":false,"shares":3863,"price":3.0229,"value":11677.4627,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.01 to $3.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":213313,"source":{"system":"sec-edgar","filing":"0000950170-24-104061","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017024104061/ownership.xml","form_type":"4"}},{"id":1413663,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":35350,"kind":"person","name":"GOOD JENNIFER L","position":1,"cik":"0001229245","reported_name":"GOOD JENNIFER L","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-09-05T20:54:52.000Z","date":"2024-09-03","kind":"exercise","planned":false,"acquired":true,"shares":3863,"price":1.43,"value":5524.09,"ownership":{"direct":true},"balance_after":217176,"source":{"system":"sec-edgar","filing":"0000950170-24-104061","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229245/000095017024104061/ownership.xml","form_type":"4"}},{"id":1419781,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-08-29T20:55:24.000Z","date":"2024-08-27","kind":"exercise","planned":false,"acquired":false,"shares":4555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on November 25, 2014. The 4,555 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal quarterly installments thereafter through November 25, 2018."}],"balance_after":0,"derivative":{"exercise_price":1.43,"expiration_date":"2024-11-24","underlying":"Common Stock","underlying_shares":4555},"source":{"system":"sec-edgar","filing":"0000950170-24-101926","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000095017024101926/ownership.xml","form_type":"4"}},{"id":1419780,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-29T20:55:24.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":4555,"price":2.9314,"value":13352.527,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.9100 to $2.9500 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":352489,"source":{"system":"sec-edgar","filing":"0000950170-24-101926","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000095017024101926/ownership.xml","form_type":"4"}},{"id":1419779,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":36265,"kind":"person","name":"Meeker David P","position":1,"cik":"0001385155","reported_name":"Meeker David P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-29T20:55:24.000Z","date":"2024-08-27","kind":"exercise","planned":false,"acquired":true,"shares":4555,"price":1.43,"value":6513.65,"ownership":{"direct":true},"balance_after":357044,"source":{"system":"sec-edgar","filing":"0000950170-24-101926","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385155/000095017024101926/ownership.xml","form_type":"4"}},{"id":1426399,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-21T16:00:02.000Z","date":"2024-08-19","kind":"exercise","planned":false,"acquired":false,"shares":16496,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018."}],"balance_after":0,"derivative":{"exercise_price":1.43,"expiration_date":"2024-11-24","underlying":"Common Stock","underlying_shares":16496},"source":{"system":"sec-edgar","filing":"0000950170-24-099481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024099481/ownership.xml","form_type":"4"}},{"id":1426398,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-21T16:00:02.000Z","date":"2024-08-19","kind":"sale","planned":false,"acquired":false,"shares":16496,"price":2.9633,"value":48882.5968,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.9000 to $3.0020 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":220315,"source":{"system":"sec-edgar","filing":"0000950170-24-099481","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024099481/ownership.xml","form_type":"4"}},{"id":1426397,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-21T16:00:02.000Z","date":"2024-08-19","kind":"exercise","planned":false,"acquired":true,"shares":16496,"price":1.43,"value":23589.28,"ownership":{"direct":true},"balance_after":236811,"source":{"system":"sec-edgar","filing":"0000950170-24-099481","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024099481/ownership.xml","form_type":"4"}}],"next_cursor":"2024-08-21T16:00:02.000000Z,1426397"}